Clinical Trial

mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2025 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to determine if immune responses differ when the mRNA COVID-19 vaccine is given through different delivery methods, including a needle-free injection system, or via intramuscular injection using needle and syringe
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-03.
Trial Details
NCT Number NCT06919796
Lead Sponsor PharmaJet, Inc.
Collaborators: Emory University
Conditions Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
Enrollment 40 participants
Start Date 2025-05-01
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-11-25 (estimated)
Updated on ClinicalTrials.gov 2025-04-15